PositiveID, a developer of medical devices for diabetes management, biological detection systems and clinical diagnostics, has developed a continuous glucose sensing system.
The system has a glucose sensor, which is an important component of PositiveID’s GlucoChip, a glucose-sensing implantable RFID microchip. The chip has the capability to precisely measure glucose levels in diabetes patients.
PositiveID has successfully laboratory-tested the closed-cycle glucose sensing system, which is stable and reproducible. The company has collaborated with Receptors to create the glucose sensing system based on Receptors’ proprietary chemistry platform. Synthetic materials, which were specifically designed, were used for the glucose sensing system. The GlucoChip technology is based on PositiveID’s VeriChip, a microchip designed for patient identification, and the company’s "Embedded Bio-Sensor System" patent. The 7,125,382 patent covers a remote transponder that wirelessly communicates with a passively-powered implantable on-chip transponder and a bio-sensor system that utilizes the RFID technology.
The components of the glucose sensing system are not based on unstable biochemical reagents such as antibodies or enzymes, but are based on simple molecular chemistry materials. Furthermore, external reagents need to be continuously added to biochemical reagents. The glucose sensing system components interact in a competitive manner with physiological blood glucose levels that keep varying, creating a measurable and reproducible response.
PositiveID plans to incorporate the electronics of the RFID microchip and a micro-electromechanical system signal transduction unit with the glucose-sensing system. This would optimize the glucose-sensing system and complete the GlucoChip’s development.